Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

3Total
P 1 (1)
P 2 (1)
P 3 (1)

Trial Status

Enrolling By Invitation1
Recruiting1
Not Yet Recruiting1
Terminated1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07855562Not Yet RecruitingPrimary

MPS IIIA Disease Monitoring Program

NCT02716246Phase 2RecruitingPrimary

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH

NCT04360265Phase 3Enrolling By Invitation

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

NCT04088734Phase 1TerminatedPrimary

Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease

Showing all 4 trials

Research Network

Activity Timeline